Recombinant SYNGR2 is utilized for:
Protein Interaction Studies: Investigating SYNGR2’s role in viral replication mechanisms, particularly its interaction with viral non-structural proteins (e.g., SFTSV NSs) to form inclusion bodies that facilitate viral RNA synthesis .
Antibody Production: Serving as an immunogen for generating antibodies used in Western blot (WB), ELISA, and protein purification arrays .
Vesicle Trafficking Assays: Studying membrane dynamics due to SYNGR2’s involvement in lipid droplet restructuring and vesicle formation .
SYNGR2 interacts with SFTSV NSs to restructure lipid droplets into viral replication factories, increasing viral RNA yield by 10–275-fold in infected cells .
In porcine models, CRISPR-edited SYNGR2 p.63Cys variants reduce PCV2 replication by 50–70%, confirming its pro-viral function .
Synaptogyrin-2 (SYNGR2) may play a role in regulated exocytosis. In neuronal cells, it modulates the localization of synaptophysin (SYP) within synaptic-like microvesicles, potentially influencing vesicle formation and/or maturation. Additionally, SYNGR2 may be involved in GLUT4 storage and transport to the plasma membrane.
SYNGR2 facilitates viral replication by reorganizing host cell structures into viral factories. Studies on severe fever with thrombocytopenia syndrome virus (SFTSV) demonstrate that SYNGR2 interacts with the viral nonstructural protein NSs to transform lipid droplets into inclusion bodies (IBs) essential for RNA replication . Methodologically, this was proven through:
Co-immunoprecipitation assays confirming SYNGR2-NSs interactions
Confocal microscopy showing SYNGR2 translocation into lipid droplets during infection
shRNA knockdown experiments reducing IB formation and viral titers by 60–80%
In esophageal squamous cell carcinoma (ESCC), SYNGR2 overexpression associates with poor prognosis and immune evasion. Key methodologies include:
Contradictions arise from species-specific interactions and experimental systems. For example:
Pro-viral activity: SYNGR2 enhances SFTSV replication in human cells by promoting IB formation
Antiviral adaptation: Domestic pigs with the SYNGR2 p.63Cys allele exhibit 40% lower porcine circovirus type 2b (PCV2b) loads compared to wild-type alleles
Contextualize model systems: Compare human (HepG2/HeLa) versus porcine (PK15) cell lines
Analyze evolutionary signatures: Detect positive selection in SYNGR2’s intraluminal loop domains across mammals
Validate interactions using orthogonal methods (e.g., in situ hybridization + proteomics)
Robust workflows integrate genetic and imaging approaches:
CRISPR/Cas9 editing to generate isogenic cell lines (e.g., PK15 SYNGR2 p.63Cys clones)
Structured illumination microscopy to resolve SYNGR2-NSs complexes in IBs (<100 nm resolution)
Crosslinking immunoprecipitation (CLIP) for mapping RNA-protein interactions during viral assembly
Long-term virus-host coevolution has shaped SYNGR2 diversity:
Population genetics: The SYNGR2 p.63Cys allele occurs in 97.7% of European domestic pigs but 0% of Asian wild boars
Functional divergence: Synergistic evolution in loop domains impacts viral entry mechanisms across mammals
| Domain | dN/dS Ratio | Positively Selected Sites |
|---|---|---|
| N-terminal luminal loop | 0.82 | 58, 63, 71 |
| Transmembrane helix 3 | 0.45 | None |
| C-terminal tail | 1.12 | 129, 135 |
| dN/dS >1 indicates positive selection |
Rescue experiments with codon-optimized SYNGR2 constructs
Time-course analyses to separate primary vs. secondary effects (e.g., measure viral RNA at 12/24/36 hpi)